NASDAQ · Biotechnology

Quince Therapeutics, Inc. (QNCX) Stock

$31.73 +8.07% NASDAQ: QNCX Healthcare

Valuation

MetricValue
Price$31.73
Market Cap$8.83M
P/E Ratio-0.46
P/B Ratio1.79
P/S Ratio0.00
EPS (TTM)$-16.80
52-Week High$910.00
52-Week Low$15.10
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-413.28%
ROA-74.58%
ROCE-107.08%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.50
Current Ratio0.53

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-90.0M$-52.0M$-35.0M$-57.0M$-50.0M
Net Profit$-90.0M$-52.0M$-31.0M$-57.0M$-84.0M
EPS$-606.00$-308.00$-168.00$-262.00$-336.00
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$133.0M$104.0M$180.0M$114.0M$94.0M
Total Liabilities$15.0M$3.0M$95.0M$84.0M$129.0M
Cash$70.0M$45.0M$21.0M$6.0M$6.0M
Borrowings$1.0M$0$14.0M$15.0M$18.0M

Latest News

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board GlobeNewswire · Jun 30, 2026 Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy Insider Monkey · Jun 2, 2026 UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD GlobeNewswire · May 18, 2026 Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD GlobeNewswire · May 18, 2026 Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-63.0M$-44.0M$-18.0M$-32.0M$-41.0M
Investing Cash Flow$59.0M$18.0M$-6.0M$22.0M$23.0M
Financing Cash Flow$0$0$0$-5.0M$0
Net Cash Flow$3.0M$-25.0M$-24.0M$-15.0M$0
Free Cash Flow$-63.0M$-44.0M$-18.0M$-32.0M$-42.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA1.48
FCF Yield-532.05%
Quick Ratio14.52
Interest Coverage0.00
Return 1Y-94.63%
Return 3Y-94.30%
Return 5Y-99.83%

Ownership

Insiders Held0.32%
Institutions Held14.20%
Institutions Float Held14.25%
Institutional HolderSharesReport Date
Gen-wealth Partners Inc 1,6512026-03-31
Catalyst Funds Management Pty Ltd1,5002026-03-31
Advisory Services Network, LLC2752026-03-31
Parallel Advisors, LLC402026-03-31
SBI Securities Co., Ltd.72026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADVMAdverum Biotechnologies, Inc. $4.36 +0.00% -0.66 $96.26M 0.00%
ALXOALX Oncology Holdings Inc. $1.25 +5.93% -1.08 $168.20M 0.00%
ATYRaTyr Pharma, Inc. $0.25 -3.56% -0.46 $24.14M 0.00%
CAMPCAMP4 Therapeutics Corporation $3.77 +1.89% -1.66 $236.58M 0.00%
CNTBConnect Biopharma Holdings Limited $0.87 -1.21% -1.05 $54.78M 0.00%

About Quince Therapeutics, Inc.

Quince Therapeutics, Inc. is led by CEO Dirk Thye, employs 36 people, headquartered in US, publicly traded since 2019.

Quince Therapeutics, Inc. (QNCX) stock trades at $31.73 with a market capitalization of $8.83M. The stock is valued at a price-to-earnings (P/E) ratio of -0.46, price-to-book of 1.79, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $15.10 and $910.00, and currently trades 96.5% below its 52-week high.

On profitability, Quince Therapeutics, Inc. generates a return on equity (ROE) of -413.28%, return on capital employed of -107.08%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides